INT247824

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 2007
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 4
Total Number 5
Disease Relevance 2.40
Pain Relevance 0.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

CDAN1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 10 81.92 Quite High
Paracetamol 2 78.00 Quite High
withdrawal 5 63.44 Quite High
rheumatoid arthritis 5 55.00 Quite High
Infliximab 148 44.40 Quite Low
corticosteroid 34 26.40 Quite Low
Potency 3 23.04 Low Low
antagonist 6 14.00 Low Low
Inflammation 75 11.76 Low Low
Adalimumab 70 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Toxicity 67 100.00 Very High Very High Very High
Recurrence 12 99.64 Very High Very High Very High
Disease 318 99.18 Very High Very High Very High
Pain 10 81.92 Quite High
Pancreatic Cancer 16 80.76 Quite High
Fistula 6 77.84 Quite High
Adenocarcinoma 4 77.16 Quite High
Abscess 10 76.84 Quite High
Death 7 68.68 Quite High
Vomiting 17 64.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Relapse was defined as a CDAI increase of >70 points or absolute CDAI >350.
Positive_regulation (increase) of CDAI associated with recurrence
1) Confidence 0.33 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.30 Pain Relevance 0.03
Relapse was defined as a CDAI increase of >70 points or absolute CDAI >350.
Positive_regulation (increase) of CDAI associated with recurrence
2) Confidence 0.33 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.30 Pain Relevance 0.03
Five patients were included in the 45 Gy cohort and they completed the planned treatment without experiencing any DLT.
Neg (without) Positive_regulation (experiencing) of DLT associated with toxicity
3) Confidence 0.29 Published 2008 Journal Radiat Oncol Section Body Doc Link PMC2557003 Disease Relevance 1.04 Pain Relevance 0
The primary endpoint was the percentage of patients achieving clinical response at week 12 (a decrease in CDAI of ?
Positive_regulation (response) of CDAI
4) Confidence 0.10 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2673818 Disease Relevance 0.20 Pain Relevance 0.03
Among the 11 responders at week 12, four maintained a response lasting for additional 4 weeks while the others had an increase in disease activity although still below baseline (mean CDAI 81 ± 64 below week 0).
Positive_regulation (mean) of CDAI associated with disease
5) Confidence 0.08 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621411 Disease Relevance 0.57 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox